The dawn phenomenon and the Somogyi effect - two phenomena of morning hyperglycaemia.

Morning hyperglycaemia in diabetic subjects may be caused by the dawn phenomenon, or the Somogyi effect, or poor glycaemic control. The dawn phenomenon occurs when endogenous insulin secretion decreases or when the effect of the exogenous insulin administered to the patient the day before disappears, together with a physiological increase in insulin-antagonistic hormones. The Somogyi effect is present in the case of excessive amounts of exogenous insulin. The dawn phenomenon is more common than the Somogyi effect. To diagnose these phenomena, it is useful to measure plasma glucose levels for several nights between 3 a.m. and 5 a.m. or use a continuous glucose monitoring system. Although their treatment differs, the best way of preventing both the dawn phenomenon and the Somogyi effect is an optimal diabetes control with insulin therapy.

[1]  A. Avignon,et al.  Morning hyperglycemic excursions: a constant failure in the metabolic control of non-insulin-using patients with type 2 diabetes. , 2002, Diabetes care.

[2]  R. K. Bernstein.  Hypoglycemia in IDDM , 1990, Diabetes Care.

[3]  E. T. Wondmagegnehu,et al.  Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes , 2009, Current medical research and opinion.

[4]  J. Moorhouse,et al.  Glucose turnover and disposal in maturity-onset diabetes. , 1973, The Journal of clinical investigation.

[5]  John Pickup,et al.  Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. , 2002, Diabetes care.

[6]  L. Guillod,et al.  Nocturnal hypoglycaemias in type 1 diabetic patients: what can we learn with continuous glucose monitoring? , 2007, Diabetes & metabolism.

[7]  Y. Touitou,et al.  Daily Profiles of Salivary and Urinary Melatonin and Steroids in Healthy Prepubertal Boys , 2009, Journal of pediatric endocrinology & metabolism : JPEM.

[8]  U. Smith,et al.  Effect of prolonged hyperglycemia on growth hormone levels and insulin sensitivity in insulin-dependent diabetes mellitus. , 1993, Metabolism: clinical and experimental.

[9]  D. Kipnis,et al.  Growth hormone secretion during sleep. , 1968, The Journal of clinical investigation.

[10]  P. Brunetti,et al.  Continuous subcutaneous insulin infusion treatment in insulin-dependent diabetic patients: a comparison with conventional optimized treatment in a long-term study. , 1982, Diabetes care.

[11]  P. Cryer.  Hierarchy of Physiological Responses to Hypoglycemia: Relevance to Clinical Hypoglycemia in Type I (Insulin Dependent) Diabetes Mellitus* , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[12]  R. Winter.  Profiles of metabolic control in diabetic children-frequency of asymptomatic nocturnal hypoglycemia. , 1981, Metabolism: clinical and experimental.

[13]  R. Holt.  Growth hormone: a potential treatment option in diabetes? , 2003 .

[14]  D. Finegold,et al.  IN SEARCH OF THE SOMOGYI EFFECT , 1980, The Lancet.

[15]  D. Schade,et al.  The dawn phenomenon revisited: implications for diabetes therapy. , 2005, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  M. Burge,et al.  Frequency of the dawn phenomenon in type 2 diabetes: implications for diabetes therapy. , 2002, Diabetes technology & therapeutics.

[17]  J. Sheehan,et al.  Fasting hyperglycemia: etiology, diagnosis, and treatment. , 2004, Diabetes technology & therapeutics.

[18]  P. Zimmet,et al.  Home Blood‐Glucose Monitoring A New Approach to the Management of Diabetes Mellitus , 1980, The Medical journal of Australia.

[19]  B. Beaufrère,et al.  Dawn phenomenon in Type 1 (insulin-dependent) diabetic adolescents: influence of nocturnal growth hormone secretion , 1988, Diabetologia.

[20]  V. Basevi.  Standards of medical care in diabetes--2007. , 2009, Diabetes care.

[21]  D. Dunger,et al.  Hypoglycaemia and Counterregulation during Childhood , 2002, Hormone Research in Paediatrics.

[22]  P. Brunetti,et al.  The effect of asymptomatic nocturnal hypoglycemia on glycemic control in diabetes mellitus. , 1988, The New England journal of medicine.

[23]  P. Cryer,et al.  Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). , 1984, The New England journal of medicine.

[24]  B. Thorsteinsson,et al.  The Somogyi phenomenon revisited using continuous glucose monitoring in daily life , 2005, Diabetologia.

[25]  P. Cryer,et al.  Failure of nocturnal hypoglycemia to cause fasting hyperglycemia in patients with insulin-dependent diabetes mellitus. , 1987, The New England journal of medicine.

[26]  F. Bernardi,et al.  Growth hormone release during sleep in growth-retarded children with normal response to pharmacological tests. , 1978, Archives of disease in childhood.

[27]  D. Dunger,et al.  A randomized cross‐over trial to identify the optimal use of insulin glargine in prepubertal children using a three‐times daily insulin regimen , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[28]  P. Raskin.  The Somogyi phenomenon. Sacred cow or bull? , 1984, Archives of internal medicine.

[29]  P. De Feo,et al.  The dawn phenomenon in Type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity , 2004, Diabetologia.

[30]  I. Macdonald,et al.  Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. , 1999, Diabetes care.

[31]  P. Schaepelynck-Belicar,et al.  Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS). , 2003, Diabetes & metabolism.

[32]  P. Brunetti,et al.  Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. , 2000, Diabetes.

[33]  H. Sanusi.  The role of incretin on diabetes mellitus. , 2009, Acta medica Indonesiana.

[34]  Efficacy, safety and tolerability of glargine - long acting insulin analogue in adult patients with type 1 diabetes mellitus in everyday clinical practice , 2007 .

[35]  Praca Oryginalna.  SkutecznoúÊ, bezpieczeæstwo i tolerancja glarginy ó d‡ugodzia‡aj"cego analogu insuliny u doros‡ych chorych na cukrzycŒ typu 1 w codziennej praktyce klinicznej , 2007 .

[36]  G. Bolli,et al.  The "dawn phenomenon"--a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. , 1984, The New England journal of medicine.

[37]  J. Buitelaar,et al.  Development of cortisol circadian rhythm in infancy. , 2003, Early human development.

[38]  I. Hirsch,et al.  Failure of Nocturnal Hypoglycemia to Cause Daytime Hyperglycemia in Patients With IDDM , 1990, Diabetes Care.

[39]  J. Wada,et al.  Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes. , 2010, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[40]  T. Jones,et al.  Decreased epinephrine responses to hypoglycemia during sleep. , 1998, The New England journal of medicine.

[41]  D. Dimić,et al.  [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy]. , 2007, Vojnosanitetski pregled.

[42]  T. Kapellen,et al.  Indications for insulin pump therapy in different age groups—an analysis of 1567 children and adolescents , 2007, Diabetic medicine : a journal of the British Diabetic Association.